Document is current

Article History

Received: 21 April 2023

Accepted: 22 August 2023

First Online: 4 October 2023

Declarations

:

: The study protocol was submitted to Western Institutional Review Board (WIRB), a central institutional review board, as the research was not conducted at the authors’ affiliated institutes. WIRB prospectively reviewed the study and considered it exempt because it is an online survey with adequate protections in place to protect the privacy of subjects and to maintain the confidentiality of data. The study and data accumulation were in conformity with all country, federal, or state laws, and the study was in adherence to the tenets of the Declaration of Helsinki. Informed consent was obtained from all participants electronically; prior to completing the online survey, participants selected a box (“I agree”) consenting to the survey terms and indicating their consent to participate.

: Not applicable.

: GG serves as a consultant for Roche Navify. SB has received consulting fees from Acadia and Novo Nordisk; he is also on the speakers’ bureau for Novo Nordisk. JP has received grants from the Arizona Alzheimer’s Disease Research Center for a research project involving cardiovascular disease, APOE, and blood biomarkers in autosomal dominant Alzheimer’s disease; he is the recipient of an Alzheimer’s Association Clinician Scientist Fellowship award examining physical activity, cardiovascular risk and their influence on AD. SA, CH, and AS are employees of and own stock in Novo Nordisk Inc.